Acadia's Alzheimer's drug failure leaves a gaping hole in its pipeline

Acadia Pharmaceuticals reported Thursday that its experimental drug for Alzheimer's-related psychosis failed to hit its main goal in a mid-stage trial, sending shares down sharply and prompting at least one analyst to cut the drug's odds of ever reaching patients to just one-in-four.

This is not a minor setback to be revised away in the next study, because a low effect size on the primary measure and questions about whether the trial could even be replicated make a credible path to approval look very narrow.

Oracle's AI data center retreat signals the buildout is harder than the hype

Oracle sent a legal notice to its financial partner in Project Jupiter, a planned $165 billion AI data center campus in New Mexico, seeking to delay payment obligations if construction slips past 2028, a move first reported by Bloomberg on Thursday.

When the company most associated with selling AI infrastructure capacity starts hedging its own ability to deliver it, that raises a real question about whether the industry's grand construction timelines are built on solid ground.

Eli Lilly's triple win today shows what a full-firing pharmaceutical engine looks like

In a single day, Eli Lilly won FDA approval for a new once-weekly insulin, signed a licensing deal worth up to $3.35 billion with a Chinese drugmaker, and saw a clinical partner file for an IPO with Lilly's backing.

While other large companies were explaining misses, Lilly's ability to advance on regulatory, commercial, and partnership fronts simultaneously is the clearest sign of how much momentum its weight-loss and cardiometabolic franchise has generated.